Skip to content

IBO - IMPACT BIOMEDICAL INC. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchI

Impact BioMedical, Inc.

IBO · AMEX

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

I

IBOImpact BioMedical, Inc.

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $0.83
52-wk low: $0.37
Prev close: $1.03
Mkt cap: $46.7M
P/E: 0.5x
P/S: 1334.5x

Smart money

7 funds hold a position.

Real smart money

Funds holding this stock

7 holders

Combined position$500K

MI
Millennium
Israel Englander · Q4 2025 13F
$70K
position
CI
Citadel
Ken Griffin · Q2 2026 13F

Earnings

Earnings

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

Fairly priced and profitable.

Net margin: 2260.0%
P/E: 0.49
Market cap: $47M

Valuation

P/S1334.52
P/B4.71

Quality

Operating margin-23400.0%

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: IBO
Exchange: AMEX
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $46.71M

Analysts

What do analysts expect?

No data yet

No analyst coverage yet for this stock.

We show it when enough analysts cover the stock.

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/B

4.7x

Profit margin

+2260.0%

Op margin

-23400.0%

ROE

+23.5%

$23K

position

TS

Two Sigma

Q2 2026 13F

$8K

position

4 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 4 holders

Coverage gaps for IBO

No recent insider trade
No recent Congress trade
No recent market-voice mention

The latest quarter is still settling.

A verdict appears once the reported figure is final

Next report

What the street expects next

ROE

23.5%

ROA-17.8%

Growth